Wellington Management Group LLP Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT)

Wellington Management Group LLP lifted its stake in Applied Therapeutics, Inc. (NASDAQ:APLT) by 17.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 237,850 shares of the company’s stock after buying an additional 35,884 shares during the period. Wellington Management Group LLP owned approximately 0.20% of Applied Therapeutics worth $204,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of APLT. SG Americas Securities LLC boosted its stake in Applied Therapeutics by 169.0% during the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock worth $35,000 after purchasing an additional 25,601 shares during the period. Private Advisor Group LLC acquired a new stake in Applied Therapeutics during the 4th quarter worth $35,000. Swiss National Bank acquired a new stake in Applied Therapeutics during the 4th quarter worth $126,000. Intech Investment Management LLC lifted its stake in shares of Applied Therapeutics by 176.1% in the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company’s stock worth $45,000 after acquiring an additional 33,567 shares during the period. Finally, Norges Bank acquired a new stake in shares of Applied Therapeutics in the 4th quarter worth $208,000. 98.31% of the stock is owned by hedge funds and other institutional investors.

Applied Therapeutics Stock Performance

APLT stock opened at $0.37 on Monday. Applied Therapeutics, Inc. has a one year low of $0.30 and a one year high of $10.62. The stock has a market capitalization of $52.27 million, a PE ratio of -0.23 and a beta of 1.86. The company has a fifty day moving average of $0.39 and a 200-day moving average of $0.92.

Applied Therapeutics (NASDAQ:APLT) last announced its quarterly earnings data on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The company had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.61 million. Equities analysts forecast that Applied Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

APLT has been the subject of several recent analyst reports. Royal Bank of Canada restated a “sector perform” rating and issued a $1.50 target price on shares of Applied Therapeutics in a research note on Wednesday, May 14th. Wall Street Zen upgraded shares of Applied Therapeutics to a “sell” rating in a research note on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $6.10.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.